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Belgium (€122,737 versus €134,679), Germany (€74,880 versus
€75,734) and Spain (€44,085 versus €44,661). In France and
Italy, lifetime costs were slightly higher in the detemir arm
(€63,605 versus €63,321 and €92,036 versus €90,139, respec-
tively), leading to incremental cost-effectiveness ratios of €519
and €3256 per QALY gained, respectively. CONCLUSIONS: The
ﬁndings of this analysis suggest that, compared to NPH, insulin
detemir is likely to be dominant in Belgium, Germany and Spain
and highly cost-effective in France and Italy in patients with type
1 diabetes.
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OBJECTIVES: Canadian payers need information comparing
the cost-effectiveness of different starter insulin therapies in
order to make relevant formulary decisions and improve T2DM
patient care. Our analyses compared the cost-effectiveness of
insulin glargine with oral antidiabetic drugs (OADs) to premixed
insulin as starter insulin therapy using published clinical data
(Janka et al, 2005) and modeling the study results to a lifetime
horizon. METHODS: The CORE Diabetes Model was used to
project lifetime clinical and economic outcomes for T2DM
patients. The baseline mean HbA1c (8.85%), age, body mass
index, gender, and duration of diabetes were taken from Janka
et al. Remaining cohort characteristics, transition probabilities,
utilities, direct treatment, and complication costs (from a Cana-
dian Provincial payer perspective) were obtained from published
sources. All costs and clinical outcomes were discounted at 5%
per annum. RESULTS: Average lifetime total direct treatment
and medical costs per patient were CAN$50,328 (+1,769) for
insulin glargine with OADs and CAN$49,555 (+1,940) for pre-
mixed insulin. Discounted life expectancy and quality-adjusted
life years (QALYs) increased by 0.051(+0.286) years and
0.215(+0.216) QALYs, respectively, for insulin glargine with
OADs compared to premixed insulin. The resulting incremental
cost-effectiveness ratios (ICERs) for insulin glargine with OADs
compared to premixed insulin were CAN$15,217/life -year
gained and CAN$3,601/QALY. CONCLUSIONS: Cost-
effectiveness for insulin glargine with OADs compared to pre-
mixed insulin was primarily driven by superior HbA1c reductions
from the Janka et al. study (-1.64% for insulin glargine with
OADs vs. -1.31% for premixed insulin, p = 0.0003) The ICERs
obtained in these analyses provide evidence for the long-term
cost-effectiveness of insulin glargine with OADs compared to
premixed insulin as an initial insulin therapy for Canadians with
T2DM.
PDB22
COST-EFFECTIVENESS OF INSULIN GLARGINE COMPARED
TO INSULIN DETEMIR FORTYPE 1 (T1DM) ANDTYPE 2
DIABETES MELLITUS (T2DM) PATIENTS INTHE CANADIAN
PAYER SETTING
Minshall ME1,Tunis SL1, Sauriol L2
1IMS Health, Noblesville, IN, USA, 2Sanoﬁ-Aventis, Laval, QC, Canada
OBJECTIVES: Canadian payers need information comparing the
cost-effectiveness of long-acting insulin analogues (LAIAs) in
order to make relevant formulary decisions. Our analyses com-
pared the cost-effectiveness of insulin glargine with insulin
detemir using published clinical data for both T1DM (Pieber
et al, 2007) and T2DM (Rosenstock et al, 2008). METHODS:
The CORE Diabetes Model was used to project lifetime clinical
and economic outcomes for T1DM and T2DM patients in sepa-
rate analyses. For T1DM, baseline mean HbA1c (8.8%), age,
body mass index, gender, and duration of diabetes were taken
from Pieber et al. For T2DM, baseline mean HbA1c (8.6%), age,
body mass index, gender, race/ethnicity, and duration of diabetes
were taken from Rosenstock et al. Remaining cohort character-
istics, transition probabilities, utilities, direct treatment, and
complication costs (from a Canadian Provincial payer perspec-
tive) were obtained from published sources for both T1DM and
T2DM analyses. All costs and clinical outcomes in both analyses
were discounted at 5% per annum. RESULTS: For T1DM,
detemir was found to have higher overall direct medical costs
(CAN$2667  4785) than glargine with a slight increase
in quality-adjusted life years (QALYs, 0.053  0.507). The
resulting incremental cost-effectiveness ratio (ICER) was
CAN$50,569/QALY for glargine compared with detemir in
T1DM. For T2DM, detemir was found to have higher overall
direct medical costs (CAN$5748  2881) than glargine with a
very slight decrease in quality-adjusted life years (QALYs,
0.005  0.259). Glargine demonstrated lower direct medical
costs and a slight improvement in QALYs compared with detemir
and is therefore a dominant strategy in T2DM. CONCLU-
SIONS: Insulin glargine demonstrated cost-effectiveness in
T1DM, consistent with current Canadian standards for health
technology assessment, and was a dominant treatment strategy in
T2DM for Canada.
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OBJECTIVES: Reduced health-related quality of life (HRQoL)
is a pronounced complication in short individuals with Growth
Hormone Deﬁciency (GHD). Current treatment options for
GHD children are limited; however, somatropin has been shown
to normalise height in childhood and adolescence compared
with no treatment. The aim of this study was to establish
whether somatropin is a cost-effective treatment for GHD
children compared with no treatment. METHODS: A cost-
effectiveness model estimated the costs and health beneﬁts over
the lifetime of GHD children. Treatment efﬁcacy was based on
Height standard deviation scores (HSDS). A Swedish health care
perspective was used. Unit costs (SEK; 2008) were obtained
from ofﬁcial sources. A 3.0% discount rate was used. Clinical
data (height, dosing and treatment duration) were obtained from
a systematic literature review (only studies with n > 300). Utility
data was derived from a published study assessing the relation
between HSDS and HRQOL. Sensitivity analyses were con-
ducted to assess the degree of uncertainty. RESULTS: Start
HSDS was -2.8 (SD 0.8) and ﬁnal HSDS was -1.5 (SD 0.8) with
somatropin treatment. Untreated children gained no HSDS. The
mean somatropin dose was 0.023 mg/kg/day over a duration of
5.1 years (SD 1.8) Over a patient’s lifetime, somatropin was
associated with a gain of 2.3 quality adjusted life years (QALYs).
Somatropin was associated with an incremental cost per QALY
of 342,592 SEK compared with no treatment. Probabilistic sen-
sitivity analysis, in which all parameters within the model were
varied, showed that there was a high probability that somatro-
pin was cost effective compared with no treatment, based on
a willingness to pay threshold of 500,000 SEK per QALY.
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